Abstract:Tumor drug resistance (TDR) invariably leads to the failure of chemotherapy. In addition, current treatment strategies for TDR are not satisfactory due to limitations in terms of safety and feasibility. The aim of the present study was to determine whether low-intensity low-frequency ultrasound (LILFU) could improve the effect of chemotherapy and reverse TDR in gemcitabine-resistant ASPC-1 (ASPC-1/GEM) cells. The investigation focused on the association between LILFU effectiveness and the adenosine triphosphate-binding cassette (ABC) transporters and the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/nuclear factor (NF)-kappa B signaling pathway. A Cell Counting Kit-8 assay was used to determine the appropriate acoustic intensity, half-maximal inhibitory concentration of gemcitabine (GEM) and the viability of ASPC-1/GEM cells. ASPC-1/GEM cells were divided into control, GEM, LILFU and GEM+LILFU groups. Cell proliferation was evaluated through colony formation assays, whereas cell apoptosis was detected using flow cytometry. Western blotting was used to explore the expression levels of ABC transporters and PI3K/AKT/NF-kappa B signaling pathway-associated proteins. Xenograft models in mice were established to identify the enhancing effect of GEM+LILFUin vivo. Immunohistochemistry was used to detect the expression levels of Ki-67 in tumor tissues. The acoustic parameter of 0.2 W/cm(2)and a GEM concentration of 6.63 mg/ml were used in subsequent experiments. Following treatment with GEM+LILFU, the cell viability and proliferation ability were decreased, whereas the apoptotic rate was increased compared with the GEM group. The expression levels of ABC transporters,PI3K-P110 alpha andNF-kappa Bwere decreased in the GEM+LILFU group. Notably, LILFU increased the effectiveness of GEM in inhibiting tumor growth, and reduced the expression levels of Ki-67 in the xenograft mouse model. LILFU improved the chemosensitivity of ASPC-1/GEM cells via inhibition of cell viability and proliferation, and promoted cell apoptosis in the GEM+LILFU group. In conclusion, LILFU may downregulate the expression levels of ABC transporters by inhibiting the PI3K-p110 alpha/AKT/NF-kappa B signaling pathway, thereby reversing resistance in pancreatic cancer.

Data from LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway

LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway

Low‑intensity Low‑frequency Ultrasound Enhances the Chemosensitivity of Gemcitabine‑resistant ASPC‑1 Cells Via PI3K/AKT/NF‑κB Pathway‑mediated ABC Transporters.

Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells.

The reciprocal loop of MALAT1 and HIF-1α facilitates gemcitabine resistance in pancreatic cancer by enhancing glycolysis

GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer Through Antiapoptotic Pathway.

Gemcitabine Treatment Causes Resistance and Malignancy of Pancreatic Cancer Stem-Like Cells Via Induction of Lncrna HOTAIR

HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression

LncRNA MACC1-AS1 induces gemcitabine resistance in pancreatic cancer cells through suppressing ferroptosis

Data from N6-methyladenosine Modification of FZR1 Mrna Promotes Gemcitabine Resistance in Pancreatic Cancer

hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma

lncRNA <i>SLC7A11</i>-<i>AS1</i> Promotes Chemoresistance by Blocking SCF<SUP>-TROP</SUP> -Mediated Degradation of NRF2 in Pancreatic Cancer

Hypoxia Potentiates Gemcitabine-Induced Stemness in Pancreatic Cancer Cells Through AKT/Notch1 Signaling

The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer

N6-methyladenosine modification of FZR1 mRNA promotes gemcitabine resistance in pancreatic cancer

LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes

HIF‐1α‐regulated stanniocalcin‐1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway

SLC39A1 Contributes to Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma by Activating AMPK Signaling

LncRNA HIF1A-AS2 mediates imatinib resistance by regulating autophagy in gastrointestinal stromal tumor cells

Hent1 Reverses Chemoresistance by Regulating Glycolysis in Pancreatic Cancer

Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis